Medtronic receives ce mark approval for affera™ mapping and ablation system to treat atrial arrhythmias

First of its kind, all-in-one sphere-9™ catheter with pulsed field ablation, radiofrequency, and high density mapping integrated with intuitive mapping and navigation platform dublin , march 15, 2023 /prnewswire/ -- medtronic (nyse:mdt) announced today that it has received ce (conformitÉ europÉenne) mark for the affera™ mapping and ablation system, which includes the sphere-9™ catheter and the affera™ prism-1 mapping software. together, the full system creates a new paradigm in electrophysiology through the unique integration of the sphere-9 pulsed field ablation (pfa), radiofrequency (rf), and high density (hd) mapping catheter, which maps and ablates atrial arrhythmias (fast, abnormal heart rhythms) and provides real-time feedback through its intuitive mapping and navigation software.
MDT Ratings Summary
MDT Quant Ranking